FDA Pauses Clozapine REMS Program Enforcement Due to High Volume of Patient Delays
The FDA has suspended a Clozapine REMS program's enforcement measures after numerous reports of patients suffering delays in getting the antipsychotic drug.
The FDA has suspended a Clozapine REMS program's enforcement measures after numerous reports of patients suffering delays in getting the antipsychotic drug.